Zavedos (Idarubicin): Uses, Dosage & Side Effects
An anthracycline cytotoxic antibiotic used in the treatment of acute myeloid leukemia and acute lymphoblastic leukemia
Zavedos (idarubicin hydrochloride) is a potent anthracycline antineoplastic antibiotic used primarily in the treatment of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). It belongs to the same drug class as doxorubicin and daunorubicin but has enhanced lipophilicity, which improves cellular uptake and contributes to its efficacy. Idarubicin works by intercalating into DNA and inhibiting topoisomerase II, thereby disrupting cell division and destroying rapidly proliferating cancer cells. Zavedos is available as oral capsules (5 mg) and is always used under strict specialist oncological supervision. Like all anthracyclines, idarubicin carries a risk of cumulative, dose-dependent cardiotoxicity and causes significant bone marrow suppression, requiring careful monitoring of cardiac function and blood counts throughout treatment.
Quick Facts: Zavedos
Key Takeaways
- Zavedos is a specialist chemotherapy drug for acute leukemia: Idarubicin is an anthracycline that destroys rapidly dividing cancer cells by damaging their DNA. It is used as part of intensive chemotherapy regimens for acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).
- Cardiotoxicity is the most critical long-term risk: Anthracyclines including idarubicin can cause cumulative, irreversible heart damage. Maximum lifetime dose limits must be strictly observed, and cardiac function must be monitored before, during, and after treatment.
- Severe bone marrow suppression is expected: Zavedos causes significant reduction in white blood cells, red blood cells, and platelets. This increases the risk of serious infections, anaemia, and bleeding. Regular blood count monitoring is essential.
- Capsules must never be opened: The contents of Zavedos capsules are cytotoxic. Direct contact with the powder can cause harm to skin, eyes, and mucous membranes. Always handle capsules carefully and store them in their original glass container.
- Effective contraception is mandatory: Both male and female patients must use reliable contraception during and after treatment (women for at least 6.5 months, men for at least 3.5 months after the last dose) due to the risk of serious harm to a developing fetus.
What Is Zavedos and What Is It Used For?
Zavedos (idarubicin) is a cytotoxic chemotherapy drug belonging to the anthracycline class. It is used to treat blood cancers, primarily acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Idarubicin works by disrupting DNA replication in cancer cells, preventing them from dividing and ultimately destroying them.
Zavedos contains the active substance idarubicin hydrochloride, which belongs to the anthracycline family of antineoplastic antibiotics. Anthracyclines are among the most effective and widely used classes of chemotherapy agents, with a history spanning over five decades in oncology. Idarubicin was developed as a structural analogue of daunorubicin, differing by the absence of a methoxy group at the C-4 position of the aglycone ring. This seemingly minor structural modification has significant pharmacological consequences: it increases the drug’s lipophilicity (fat solubility), enhances cellular uptake, improves oral bioavailability, and may contribute to greater potency against certain leukemia cell lines.
In acute leukemia, the normal process of blood cell maturation in the bone marrow is disrupted. Instead of developing into functional white blood cells, red blood cells, and platelets, immature and dysfunctional blast cells accumulate. These blast cells crowd out normal blood cell production, leading to anaemia, immune deficiency, and bleeding problems. Zavedos targets these rapidly dividing blast cells through multiple mechanisms of action, helping to restore normal bone marrow function.
How Idarubicin Works
Idarubicin exerts its cytotoxic effects through several interconnected mechanisms. The primary mechanism involves DNA intercalation, where the planar anthracycline ring system inserts itself between adjacent base pairs in the DNA double helix. This distorts the DNA structure and interferes with the activity of enzymes critical for DNA replication and transcription.
The second key mechanism is the inhibition of topoisomerase II, an enzyme that is essential for managing the topology of DNA during replication. Topoisomerase II normally creates temporary double-strand breaks in DNA to relieve torsional strain, then reseals the breaks. Idarubicin stabilises the cleavable complex between topoisomerase II and DNA, preventing the re-ligation step and resulting in permanent DNA strand breaks that trigger cell death (apoptosis).
Additionally, idarubicin generates free radicals through iron-mediated oxidative reactions. These highly reactive molecules cause further damage to DNA, cell membranes, and intracellular proteins, contributing to the drug’s overall cytotoxic effect. However, this free radical generation is also believed to be a key contributor to the cardiotoxicity associated with anthracycline therapy.
Clinical Indications
Zavedos oral capsules are primarily indicated for the following conditions:
- Acute myeloid leukemia (AML): As part of induction and consolidation chemotherapy, often in combination with cytarabine. The idarubicin–cytarabine combination is one of the standard “3+7” induction regimens recommended by ESMO and NCCN guidelines
- Acute lymphoblastic leukemia (ALL): As a component of multi-agent chemotherapy protocols, particularly in relapsed or refractory disease
Zavedos is available as both oral capsules and an intravenous formulation. The oral capsule form offers convenience and may be used in certain treatment phases or clinical settings. However, oral bioavailability is variable (approximately 18–39%), and the choice between oral and intravenous administration depends on the specific clinical scenario, patient factors, and institutional protocols. Your oncologist will determine the most appropriate route of administration for your treatment plan.
What Should You Know Before Taking Zavedos?
Before starting treatment with Zavedos, your oncologist will perform a comprehensive assessment including cardiac function testing, blood counts, and liver and kidney function tests. Several conditions absolutely contraindicate the use of idarubicin, and many others require careful evaluation and monitoring.
Contraindications – Do Not Use Zavedos If You:
- Are allergic to idarubicin hydrochloride or any of the other ingredients in the capsule
- Have severely impaired kidney function
- Have significant cardiac dysfunction, including heart failure or severely reduced ejection fraction
- Have recently experienced a myocardial infarction (heart attack)
- Have severe cardiac arrhythmias (irregular heartbeat)
- Have persistent bone marrow suppression from previous chemotherapy or radiotherapy
- Have previously received the maximum cumulative lifetime dose of idarubicin or other anthracyclines (such as doxorubicin or daunorubicin) or anthracenediones
Warnings and Precautions
Talk to your oncologist, pharmacist, or specialist nurse before starting treatment with Zavedos if you have any of the following conditions or circumstances, as they may affect your treatment plan or require additional monitoring:
- Pre-existing heart disease: Any history of cardiac problems, including coronary artery disease, valvular heart disease, or previous cardiac events, increases the risk of anthracycline-induced cardiotoxicity
- Significant bone marrow suppression: If you already have very low blood cell counts from any cause, idarubicin will further suppress bone marrow function
- Liver disease: Idarubicin is extensively metabolised in the liver, and impaired liver function can lead to increased drug exposure and toxicity. Dose adjustments may be necessary
- Kidney disease: Although renal elimination is not the primary excretion route, significant renal impairment may affect drug clearance
- Active or uncontrolled infections: Because Zavedos suppresses the immune system, any existing infection must be adequately treated before starting chemotherapy
- Previous anthracycline therapy: Cardiotoxicity is cumulative across all anthracyclines. Your oncologist will calculate your total lifetime anthracycline exposure
- Prior radiotherapy to the chest: Radiation to the mediastinum or cardiac region increases the risk of anthracycline-induced heart damage
- Previous bone marrow transplantation: This may affect your tolerance to further chemotherapy
If you have been treated with trastuzumab (used for certain types of cancer, particularly HER2-positive breast cancer), inform your oncologist. Trastuzumab can remain in the body for up to 7 months after the last dose and can affect cardiac function. Zavedos should not be used within 7 months of trastuzumab treatment unless cardiac function is carefully monitored, as the combination significantly increases the risk of cardiotoxicity.
Zavedos capsules must never be opened, crushed, chewed, or broken. The powder inside the capsule is cytotoxic and can cause harm if it comes into contact with skin, eyes, or mucous membranes. Always store capsules in their original brown glass container with the child-resistant screw cap. If a capsule accidentally breaks and the contents come into contact with the skin, eyes, or mouth, rinse immediately with copious amounts of water and contact a doctor.
Pregnancy and Breastfeeding
Zavedos can cause serious harm to an unborn baby. It is essential that pregnancy is avoided during treatment and for a defined period afterwards. The following guidance applies:
- Women who can become pregnant: Must use effective contraception during treatment with Zavedos and for at least 6.5 months after the last dose. Tell your doctor immediately if you think you may be pregnant
- Men: Must use effective contraception during treatment and for at least 3.5 months after the last dose
- Breastfeeding: Do not breastfeed during treatment with Zavedos and for at least 14 days after the last dose. The drug or its metabolites may pass into breast milk and could harm the baby
- Fertility: Zavedos may impair fertility in both men and women. Discuss fertility preservation options (such as sperm banking or egg freezing) with your oncologist before starting treatment
Driving and Using Machines
It is not known whether Zavedos directly affects the ability to drive or operate machinery. However, chemotherapy frequently causes fatigue, nausea, dizziness, and general malaise that may impair your ability to perform tasks requiring concentration. You should assess your own condition before driving or operating machinery and discuss any concerns with your medical team.
How Does Zavedos Interact with Other Drugs?
Zavedos can interact with several other medications, particularly other cardiotoxic drugs, immunosuppressants, and live vaccines. Because idarubicin is used as part of multi-agent chemotherapy protocols, potential interactions are carefully managed by the oncology team.
As a potent cytotoxic agent that is extensively metabolised by the liver and has significant effects on the bone marrow and immune system, idarubicin has the potential to interact with many other medications. Your oncology team will carefully review all your current medications before starting treatment. It is important to inform them about all prescription drugs, over-the-counter medications, herbal supplements, and vitamins you are taking.
Major Interactions
| Drug / Class | Type of Interaction | Clinical Significance |
|---|---|---|
| Trastuzumab | Increased cardiotoxicity | Do not use within 7 months of trastuzumab. Both drugs independently damage the heart; the combination is synergistically cardiotoxic. |
| Other anthracyclines (doxorubicin, daunorubicin, epirubicin) | Cumulative cardiotoxicity | Cardiotoxicity is cumulative across all anthracyclines. Lifetime dose limits apply to the total combined exposure. |
| Live vaccines (MMR, varicella, yellow fever, oral polio) | Risk of vaccine-induced infection | Immunosuppression from Zavedos means live vaccines can cause the disease they are meant to prevent. Avoid during and after treatment. |
| Ciclosporin | Altered drug metabolism | May increase idarubicin exposure and toxicity. Requires careful monitoring and potential dose adjustment. |
| Cytarabine | Additive myelosuppression | Commonly used together therapeutically (3+7 regimen) but the combination causes profound bone marrow suppression requiring intensive monitoring. |
Additional Interactions to Be Aware Of
- Hepatotoxic drugs: Medications that affect liver function may alter the metabolism of idarubicin, potentially increasing toxicity
- Anticoagulants (e.g., warfarin): Zavedos-induced thrombocytopenia increases bleeding risk; anticoagulant doses may need adjustment
- Phenytoin and other enzyme-inducing anticonvulsants: May alter idarubicin metabolism and reduce its efficacy
- Cardiotoxic medications: Any other medications with potential cardiac side effects (such as certain targeted therapies, fluoropyrimidines, or antiarrhythmics) should be used with extreme caution
- Nephrotoxic agents: Medications that impair kidney function may reduce the renal excretion of idarubicin and its metabolites
What Is the Correct Dosage of Zavedos?
Zavedos dosage is determined individually by your oncologist based on the type and stage of your leukemia, your body surface area, previous treatments, and organ function. Oral treatment is typically given in cycles of 3 consecutive days followed by a rest period.
The dosage of Zavedos is highly individualised and must always be determined by a specialist oncologist or haematologist experienced in the use of cytotoxic chemotherapy. The dose is calculated based on body surface area (BSA), which takes into account your height and weight. Never attempt to adjust your dose without consulting your oncologist, and always follow their instructions precisely.
Adults
Standard Oral Dosing
Treatment is given in cycles. A typical oral regimen involves taking Zavedos capsules for 3 consecutive days, followed by a rest period to allow blood cell counts to recover. The standard oral dose ranges from 15–30 mg/m² per day for 3 days, either as monotherapy or as part of a combination regimen. The exact dose, number of cycles, and duration of rest periods depend on the treatment protocol, disease response, and the patient’s tolerance.
Multiple treatment cycles are usually required before the therapeutic response can be fully evaluated. Your oncologist will monitor your blood counts and organ function closely between cycles to determine when it is safe to proceed with the next cycle.
Children
Paediatric Dosing
The use of Zavedos in children is determined by paediatric oncology protocols. Dosing in children follows specialised guidelines and is based on body surface area, age, and the specific treatment protocol being used. Paediatric dosing requires careful consideration of the child’s developing organs, particularly the heart. All decisions regarding dosage in children are made by experienced paediatric oncologists.
Dose Adjustments
Hepatic and Renal Impairment
Dose reductions are required for patients with impaired liver or kidney function. Since idarubicin is extensively metabolised in the liver, elevated bilirubin levels typically necessitate a dose reduction of 25–50%. In severe hepatic impairment, Zavedos is contraindicated. Similarly, significant renal impairment (serum creatinine > 2 mg/dL) may require dose modification. Your oncologist will adjust your dose based on regular liver and kidney function tests.
How to Take Zavedos Capsules
- Check that the capsules are intact before taking them
- Swallow the capsules whole with at least half a glass of water
- Do not open, bite, suck, or chew the capsules
- Do not split or crush the capsules
- If a capsule appears damaged, do not take it – inform your pharmacist
Missed Dose
If you miss a dose of Zavedos, contact your oncologist or specialist nurse immediately for advice. Do not take a double dose to make up for a missed one. Because Zavedos is given in short treatment cycles with precisely calculated timing, any deviation from the prescribed schedule should be discussed with your medical team.
Overdose
If you or someone else accidentally takes too much Zavedos, or if a child accidentally ingests the medication, seek emergency medical attention immediately. Overdose with idarubicin is expected to cause severe bone marrow suppression (with a nadir typically occurring 10–14 days after administration), gastrointestinal toxicity (severe mucositis, nausea, vomiting, and diarrhoea), and potentially acute cardiac toxicity. There is no specific antidote for idarubicin overdose; treatment is supportive, including blood transfusions, antibiotics for infection, and cardiac monitoring.
What Are the Side Effects of Zavedos?
Like all chemotherapy drugs, Zavedos causes side effects in most patients. Many of these effects are serious and require close medical monitoring. The most common side effects include bone marrow suppression, nausea, vomiting, hair loss, mouth sores, and red discolouration of urine. Always contact your oncologist if you experience any new or worsening symptoms.
Treatment with Zavedos frequently causes side effects, and many of these can be severe. It is essential that you maintain close contact with your oncology team throughout treatment and report any new symptoms promptly. Your medical team will use supportive medications and other strategies to help manage side effects and will adjust your treatment if necessary.
Very Common
- Infections (bacterial, viral, or fungal due to immune suppression)
- Decreased platelet count (thrombocytopenia) – risk of bleeding
- Decreased white blood cell count (leukopenia and neutropenia) – risk of serious infections
- Anaemia (low red blood cell count) – causing fatigue and breathlessness
- Decreased appetite
- Nausea and vomiting
- Inflammation and sores in the mouth and throat (mucositis/stomatitis)
- Diarrhoea
- Abdominal pain or burning sensation
- Hair loss (alopecia) – usually temporary
- Red discolouration of urine for 1–2 days after treatment (harmless)
- Fever (pyrexia)
- Headache
- Chills
Common
- Bone marrow failure (myelosuppression)
- Heart failure (cardiomyopathy)
- Changes in heart rhythm (arrhythmias)
- Bleeding (haemorrhage)
- Inflammation or blood clots in superficial veins (thrombophlebitis)
- Gastrointestinal bleeding
- Stomach pain
- Abnormal liver function tests
- Skin rash and itching (pruritus)
- Increased sensitivity of previously irradiated skin (radiation recall)
Uncommon
- Sepsis (blood poisoning) – a life-threatening infection
- Secondary leukemia (treatment-related cancer)
- Dehydration
- Elevated uric acid levels (hyperuricaemia)
- Myocardial infarction (heart attack)
- ECG changes
- Shock
- Inflammation of the oesophagus and intestines (oesophagitis, enterocolitis)
- Urticaria (hives)
- Increased pigmentation of skin and nails
- Cellulitis (tissue inflammation)
- Tissue necrosis (death) if the drug leaks outside a vein
Rare
- Cerebral haemorrhage (bleeding in the brain)
Very Rare
- Severe allergic reactions (anaphylaxis)
- Pericarditis (inflammation of the membrane around the heart)
- Myocarditis (inflammation of the heart muscle)
- Cardiac conduction disorders (heart block)
- Thromboembolism (blood clot in a vein or artery)
- Flushing (hot flushes)
- Gastric ulcers
- Erythema (skin redness)
Frequency Not Known
- Pancytopenia (severe reduction of all blood cell types)
- Tumour lysis syndrome (rapid breakdown of cancer cells causing metabolic disturbances)
- Chronic heart failure
- Increased pigmentation of oral mucosa
- Skin changes
- Nail detachment (onycholysis)
Contact your oncologist or go to the emergency department immediately if you experience: fever above 38°C (possible sign of neutropenic sepsis), unusual bleeding or bruising, chest pain, breathlessness, or swollen ankles (possible signs of heart failure), severe diarrhoea or vomiting that prevents you from eating or drinking, or signs of a severe allergic reaction (difficulty breathing, swelling of the face or throat).
How Should You Store Zavedos?
Store Zavedos capsules out of the sight and reach of children. Keep them in the original brown glass container with the child-resistant cap to protect the capsules from breakage. No special temperature storage conditions are required.
Proper storage of Zavedos is particularly important because the capsules contain cytotoxic material. If a capsule breaks, the powder inside can cause harm upon contact with skin or mucous membranes. The following storage guidelines should be followed:
- Keep out of the sight and reach of children at all times
- Store in the original brown glass container with the child-resistant screw cap
- No special temperature storage conditions are required
- Do not use after the expiry date printed on the packaging (the expiry date refers to the last day of the stated month)
- Do not dispose of via household waste or down the drain
- Return unused or expired capsules to your pharmacy for safe disposal – this protects the environment and prevents accidental exposure
Because Zavedos is a cytotoxic medication, it must be disposed of according to local regulations for hazardous pharmaceutical waste. Never place unused capsules in regular household rubbish. Your pharmacy or hospital can advise on the correct disposal procedure in your area.
What Does Zavedos Contain?
Each Zavedos hard capsule contains 5 mg of idarubicin hydrochloride as the active substance, along with several inactive ingredients that make up the capsule shell and printing ink.
Active Ingredient
The active substance is idarubicin hydrochloride 5 mg per capsule. Idarubicin is the 4-demethoxy analogue of daunorubicin, an anthracycline antibiotic originally isolated from Streptomyces peucetius. The hydrochloride salt form is used to improve stability and solubility.
Inactive Ingredients (Excipients)
- Microcrystalline cellulose – a filler and binder
- Glyceryl palmitostearate – a lubricant
Capsule Shell
- Gelatin – forms the capsule shell
- Titanium dioxide (E171) – white colourant
- Red iron oxide (E172) – colourant giving the capsule its distinctive colour
Printing Ink
The printing ink on the capsule contains trace amounts of shellac, black iron oxide (E172), propylene glycol, potassium hydroxide, and concentrated ammonia.
Capsule Appearance
Zavedos 5 mg capsules are hard gelatin capsules with a distinctive appearance. They are packaged in brown glass jars with a child-resistant screw cap to ensure safe storage and minimize the risk of capsule breakage.
Manufacturer
Zavedos is manufactured by Latina Pharma S.p.A. in Sermoneta, Italy, and is marketed by Pfizer in many countries worldwide. It is also available under the brand name Idamycin in some markets.
Frequently Asked Questions About Zavedos
Zavedos (idarubicin) is an anthracycline chemotherapy medication used primarily for the treatment of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). It works by damaging the DNA of rapidly dividing cancer cells, preventing them from multiplying. In AML, idarubicin is commonly used as part of induction chemotherapy in combination with cytarabine (the “3+7” regimen), and has been shown to be at least as effective as daunorubicin with potentially superior complete remission rates in some patient populations.
The most serious side effects of Zavedos include cardiotoxicity (heart damage that can lead to heart failure), severe bone marrow suppression leading to dangerously low blood cell counts (neutropenia, thrombocytopenia, anaemia), and life-threatening infections due to immune suppression. Cardiotoxicity is cumulative and dose-dependent – once the maximum lifetime dose of anthracyclines is reached, the risk of irreversible heart damage increases significantly. Regular monitoring of heart function with echocardiography or MUGA scans is essential throughout treatment.
No, Zavedos capsules must never be opened, crushed, chewed, or broken. The contents of the capsule are cytotoxic (cell-damaging), and direct contact with the powder can cause harm to the skin, eyes, and mucous membranes. Capsules should always be stored in their original glass container to minimize the risk of breakage. If a capsule breaks and the contents come into contact with skin, eyes, or mouth, rinse the affected area immediately with copious amounts of water and contact a doctor.
Idarubicin, the active substance in Zavedos, is red in colour. When it is metabolised and excreted by the body, it can cause the urine to turn red or orange for 1 to 2 days after each dose. This is a harmless and expected effect of the medication – it does not indicate blood in the urine or any dangerous reaction. Patients should be informed about this effect before starting treatment to avoid unnecessary alarm.
Zavedos treatment is given in cycles. A typical oral treatment cycle involves taking capsules for 3 consecutive days followed by a rest period to allow the bone marrow and blood cell production to recover. Multiple treatment cycles are usually required before the response can be fully evaluated. The exact number of cycles depends on the type and stage of leukemia, the patient’s response to treatment, blood count recovery, and overall tolerance. Your oncologist will determine the optimal treatment duration based on regular assessments of disease status and organ function.
Live vaccines (such as MMR, varicella, yellow fever, and oral polio) must be avoided during treatment with Zavedos and for a period after treatment ends. Zavedos suppresses the immune system, which means live vaccines could potentially cause the infection they are designed to prevent. Inactivated vaccines (such as influenza and pneumococcal vaccines) may be given but their effectiveness may be reduced due to immunosuppression. Always consult your oncologist before receiving any vaccination during or after chemotherapy.
References
- Berman E, Heller G, Santorsa J, et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood. 1991;77(8):1666-1674. doi:10.1182/blood.V77.8.1666.1666
- Wiernik PH, Banks PL, Case DC Jr, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood. 1992;79(2):313-319. doi:10.1182/blood.V79.2.313.313
- Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and Management of AML in Adults: 2022 ELN Recommendations from an International Expert Panel. Blood. 2022;140(12):1345-1377. doi:10.1182/blood.2022016867
- European Medicines Agency (EMA). Zavedos (Idarubicin) – Summary of Product Characteristics. Accessed December 2025.
- Heuser M, Ofran Y, Boissel N, et al. Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2020;31(6):697-712. doi:10.1016/j.annonc.2020.02.018
- National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia. Version 3.2025. Accessed December 2025.
- World Health Organization. WHO Model List of Essential Medicines – 23rd list (2023). Geneva: World Health Organization; 2023.
- Cardinale D, Colombo A, Bacchiani G, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131(22):1981-1988. doi:10.1161/CIRCULATIONAHA.114.013777
- Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). European Heart Journal. 2022;43(41):4229-4361. doi:10.1093/eurheartj/ehac244
- British National Formulary (BNF). Idarubicin hydrochloride. National Institute for Health and Care Excellence (NICE). Updated 2025.
Editorial Team
This article has been written and reviewed by the iMedic medical editorial team according to our strict editorial standards. Our team consists of licensed physicians, pharmacists, and medical researchers with expertise in clinical oncology, haematology, and chemotherapy safety.
Content developed by iMedic’s medical writing team based on current international guidelines (WHO, EMA, FDA, ESMO, NCCN, ELN) and peer-reviewed oncological research.
Independently reviewed and fact-checked by the iMedic Medical Review Board, comprising board-certified specialists in clinical oncology, haematology, and clinical pharmacology.
All medical claims are supported by Level 1A evidence (systematic reviews, meta-analyses, and randomized controlled trials) following the GRADE evidence framework.
iMedic receives no commercial funding from pharmaceutical companies. All content is editorially independent with no conflicts of interest.